Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: A retrospective analysis of 15 patients

Thrombosis Research

Volumn 112, Issue 4, 2003, Pages 229-232

  Bachleitner Hofmann, Thomas ^a   Grumbeck, Elke ^a   Gisslinger, Heinz ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Oral anticoagulants; Polycythemia vera; Secondary prophylaxis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BUDD CHIARI SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LOW DRUG DOSE; MALE; POLYCYTHEMIA VERA; PORTOSYSTEMIC ANASTOMOSIS; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; RETROSPECTIVE STUDY; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 1342345211     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.12.015     Document Type: Article

References (12)

1. Pearson T.C., Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet. 2:1978;1219-1222.
2. Schafer A.I. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 64:1984;1-12.
3. Brodmann S., Passweg J.R., Gratwohl A., Tichelli A., Skoda R.C. Myeloproliferative disorders: complications, survival and causes of death. Ann. Hematol. 79:2000;312-318.
4. Wehmeier A., Sudhoff T., Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin. Thromb. Hemost. 23:1997;391-402.
5. Barbui T., Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin. Thromb. Hemost. 23:1997;455-461.
6. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann. Intern. Med. 123:1995;656-664.
7. Spivak J.L. Polycythemia vera: myths, mechanisms, and management. Blood. 100:2002;4272-4590.
8. Michiels J.J., Barbui T., Finazzi G., Fruchtmann S.M., Kutti J., Rain J.D.et al. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk. Lymphoma. 36:2000;239-253.
9. Heis N., Rintelen C., Gisslinger B., Knöbl P., Lechner K., Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur. J. Haematol. 62:1999;27-31.
10. Berk P.D., Goldberg J.D., Donovan P.B., Fruchtman S.M., Berlin N.I., Wasserman L.R. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin. Hematol. 23:1986;132-143.
11. Low-dose aspirin in polycythemia vera: a pilot study. Br. J. Haematol. 97:1997;453-456.
12. Landdfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., Barbui T. Efficacy and safety of low-dose aspirin in polycythemia verra. N. Engl. J. Med. 350:2004;114-124.